MedTrace Logo

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

NCT06142656 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-30

No results posted yet for this study

Summary

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM

Conditions

  • Poly Cystic Ovary Syndrome

Interventions

DRUG

Metformin Hydrochloride tablet

Metformin Hydrochloride 850 mg oral tablet

DRUG

Vildagliptin 50 MG

Vildagliptin 50 MG oral tablets

Sponsors & Collaborators

  • October 6 University

    lead OTHER

Principal Investigators

  • ahmed hussein, PhD · october 6 university hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-25
Primary Completion
2025-12-01
Completion
2026-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06142656 on ClinicalTrials.gov